Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Illinois Cancer Specialists
mi
from
Arlington Heights, IL
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Illinois Cancer Specialists
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Lurie Children's Hospital of Chicago Developmental Therapeutics
mi
from
Chicago, IL
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Lurie Children's Hospital of Chicago Developmental Therapeutics
mi
from
Chicago, IL
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Indiana University Indiana Univ. - Purdue Univ.
mi
from
Indianapolis, IN
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Indiana University Indiana Univ. - Purdue Univ.
mi
from
Indianapolis, IN
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Northern Indiana Cancer Research Consortium No. Indiana Cancer Res.
mi
from
South Bend, IN
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Northern Indiana Cancer Research Consortium No. Indiana Cancer Res.
mi
from
South Bend, IN
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
University of Louisville / James Graham Brown Cancer Center SC
mi
from
Louisville, KY
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
University of Louisville / James Graham Brown Cancer Center SC
mi
from
Louisville, KY
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
St. Agnes Hospital St. Agnes Hospital (2)
mi
from
Baltimore, MD
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
St. Agnes Hospital St. Agnes Hospital (2)
mi
from
Baltimore, MD
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Southcoast Centers for Cancer Care
mi
from
Fairhaven, MA
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Southcoast Centers for Cancer Care
mi
from
Fairhaven, MA
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Cancer and Hematology Centers of West Michigan, PC Dept of Oncology
mi
from
Grand Rapids, MI
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Cancer and Hematology Centers of West Michigan, PC Dept of Oncology
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Research Medical Center Research Med Center (2)
mi
from
Kansas City, MO
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Research Medical Center Research Med Center (2)
mi
from
Kansas City, MO
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center Dartmouth Hitchcock - Lebanon
mi
from
Bedford, NH
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center Dartmouth Hitchcock - Lebanon
mi
from
Bedford, NH
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
New Mexico Cancer Center
mi
from
Albuquerque, NM
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Waverly Hematology Oncology
mi
from
Cary, NC
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Waverly Hematology Oncology
mi
from
Cary, NC
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Duke University Medical Center Seeley G. Mudd Bldg.
mi
from
Durham, NC
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Duke University Medical Center Seeley G. Mudd Bldg.
mi
from
Durham, NC
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Sanford Hematology Oncology
mi
from
Fargo, ND
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Sanford Hematology Oncology
mi
from
Fargo, ND
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Oncology Hematology Care, Inc. Oncology Hematology Care (2)
mi
from
Cincinnati, OH
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Oncology Hematology Care, Inc. Oncology Hematology Care (2)
mi
from
Cincinnati, OH
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
University Hospitals of Cleveland Seidman Cancer Center University Hospitals
mi
from
Cleveland, OH
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
University Hospitals of Cleveland Seidman Cancer Center University Hospitals
mi
from
Cleveland, OH
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
The Cleveland Clinic Foundation-Taussig Cancer Institute
mi
from
Cleveland, OH
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
The Cleveland Clinic Foundation-Taussig Cancer Institute
mi
from
Cleveland, OH
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Bend Memorial Clinic Bend Mem. Clinic
mi
from
Bend, OR
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Bend Memorial Clinic Bend Mem. Clinic
mi
from
Bend, OR
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Northwest Cancer Specialists Northwest Cancer
mi
from
Portland, OR
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Northwest Cancer Specialists Northwest Cancer
mi
from
Portland, OR
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Lehigh Valley Health Network
mi
from
Allentown, PA
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Lehigh Valley Health Network
mi
from
Allentown, PA
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Cancer Institute Hillman Cancer Center (2)
mi
from
Pittsburgh, PA
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Cancer Institute Hillman Cancer Center (2)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Rhode Island Hospital Rhode Island Hosp. (2)
mi
from
Providence, RI
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Rhode Island Hospital Rhode Island Hosp. (2)
mi
from
Providence, RI
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Tennessee Oncology Tennessee Oncology (3)
mi
from
Nashville, TN
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Tennessee Oncology Tennessee Oncology (3)
mi
from
Nashville, TN
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Oncology Consultants Oncology Group
mi
from
Houston, TX
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Oncology Consultants Oncology Group
mi
from
Houston, TX
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Houston Methodist Cancer Center
mi
from
Houston, TX
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Houston Methodist Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3)
mi
from
Houston, TX
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3)
mi
from
Houston, TX
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Texas Oncology PA
mi
from
McAllen, TX
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Texas Oncology PA
mi
from
McAllen, TX
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Cancer Therapy & Research Center / UT Health Science Center Oncology Dept.
mi
from
San Antonio, TX
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Cancer Therapy & Research Center / UT Health Science Center Oncology Dept.
mi
from
San Antonio, TX
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Deke Slayton Cancer Center Deke Slayton Cancer Center (2)
mi
from
Webster, TX
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Deke Slayton Cancer Center Deke Slayton Cancer Center (2)
mi
from
Webster, TX
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Intermountain Medical Center Intermountain Healthcare
mi
from
Murray, UT
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Intermountain Medical Center Intermountain Healthcare
mi
from
Murray, UT
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Northern Utah Cancer Associates Northern Utah Assoc (3)
mi
from
Ogden, UT
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Northern Utah Cancer Associates Northern Utah Assoc (3)
mi
from
Ogden, UT
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
University of Utah / Huntsman Cancer Institute SC-2
mi
from
Salt Lake City, UT
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
University of Utah / Huntsman Cancer Institute SC-2
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Utah Cancer Specialists Utah Cancer Specialists (11)
mi
from
Salt Lake City, UT
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Utah Cancer Specialists Utah Cancer Specialists (11)
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Virginia Cancer Specialists, PC Fairfax Northern Virginia
mi
from
Fairfax, VA
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Virginia Cancer Specialists, PC Fairfax Northern Virginia
mi
from
Fairfax, VA
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Shenandoah Oncology Shenandoah Oncology (5)
mi
from
Winchester, VA
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Shenandoah Oncology Shenandoah Oncology (5)
mi
from
Winchester, VA
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Northwest Medical Specialties NW Medical Specialties
mi
from
Tacoma, WA
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Northwest Medical Specialties NW Medical Specialties
mi
from
Tacoma, WA
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
San Francisco General Hospital San Francisco Gen Hosp (7)
mi
from
San Francisco, CA
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
San Francisco General Hospital San Francisco Gen Hosp (7)
mi
from
San Francisco, CA
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Norwalk Hospital
mi
from
Norwalk, CT
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Norwalk Hospital
mi
from
Norwalk, CT
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists Florida Cancer Specialists 36
mi
from
Fort Myers, FL
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists Florida Cancer Specialists 36
mi
from
Fort Myers, FL
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
University of Miami Sylvester Comprehensive Cancer
mi
from
Miami, FL
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
University of Miami Sylvester Comprehensive Cancer
mi
from
Miami, FL
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Community Clinical Research Center
mi
from
Anderson, IN
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Community Clinical Research Center
mi
from
Anderson, IN
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Minnesota Oncology Hematology, P.A. Minnesota Oncology Hem (27)
mi
from
Minneapolis, MN
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Minnesota Oncology Hematology, P.A. Minnesota Oncology Hem (27)
mi
from
Minneapolis, MN
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Wake Forest Baptist Health Hem & Onc Medical Center
mi
from
Winston-Salem, NC
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Wake Forest Baptist Health Hem & Onc Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Sanford University of South Dakota Medical Center Sanford Health
mi
from
Sioux Falls, SD
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Sanford University of South Dakota Medical Center Sanford Health
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology
mi
from
Chattanooga, TN
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology
mi
from
Chattanooga, TN
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Texas Oncology Cancer Care & Research Center Texas Oncology
mi
from
Waco, TX
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Texas Oncology Cancer Care & Research Center Texas Oncology
mi
from
Waco, TX
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Billings Clinic Billings Clinic (8)
mi
from
Billings Montana, MT
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Billings Clinic Billings Clinic (8)
mi
from
Billings Montana, MT
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Cancer Treatment Centers of America Eastern Regional Medical Center
mi
from
Philadelphia, PA
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Cancer Treatment Centers of America Eastern Regional Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials